Vanda Pharmaceuticals (VNDA) Peer Comparison

$5.29

$-0.15 (-2.76%)

As on 28-Aug-2026 16:00EDT

Market cap

$319 Mln

Revenue (TTM)

$216 Mln

P/E Ratio

--

P/B Ratio

1.5

Div. Yield

0 %

Edit

	Vanda Pharmaceuticals (VNDA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Market cap ($ Mln)	319	17,326	16,614	13,400	12,305
Revenue ($ Mln)	216	2,782	1,054	2,436	670
Net Profit ($ Mln)	-274.85	491.50	755.85	860.62	-319.95
Net Margin (%)	-127.41	17.67	71.69	35.33	-47.79
RoE (%)	-100.43	110.09	--	42.98	-71.14
Price to Earnings	--	36.49	19.38	17.01	--
Price-To-Book	1.47	39.43	10.05	7.27	26.44

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Vanda Pharmaceuticals (VNDA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Operating Revenue	215.72	2,782.29	1,054.37	2,435.92	669.50
Cost of Revenue	15.49	1,982.07	103.47	85.67	19.14
Gross Profit	203.06	760.62	588.53	2,236.43	829.45
Operating Expenses	385.90	216.81	841.45	1,378.74	895.93
Operating Profit (EBIT)	-185.67	583.40	109.45	971.51	-226.44
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-177.20	598.92	101.11	1,035.47	-252.08
Provision for Tax	97.65	107.42	-654.74	174.84	20.05
Profit after Tax (Net Income)	-274.85	491.50	755.85	860.62	-319.95
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Vanda Pharmaceuticals (VNDA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Shareholder's Funds	220.19	433.86	1,435.90	1,843.76	465.53
Minority Interest	0.00	0.00	0.00	0.00	-47.83
Non-Current Liabilities	28.26	187.89	384.48	288.55	1,362.63
Current Liabilities	164.03	1,435.43	464.70	361.93	283.35
Total Liabilities	488.95	1,975.47	1,302.02	2,844.42	1,385.30

Assets ($ Mln)

	Vanda Pharmaceuticals (VNDA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Non-Current Assets	147.98	1,006.90	895.24	1,243.41	440.60
Current Assets	264.48	1,050.29	1,389.84	1,250.82	1,671.41
Total Assets	488.95	1,975.47	1,302.02	2,844.42	1,385.30
Total Debt*	22.83	120.10	449.89	165.93	864.07
Net Current Assets	100.46	-385.14	0.00	888.90	1,388.07

Cashflow ($ Mln)

	Vanda Pharmaceuticals (VNDA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Cash From Operating Activities	-109.44	713.22	51.77	884.27	179.55
Cash Flow from Investing Activities	94.86	-31.14	-8.15	350.44	-129.29
Cash from Financing Activities	-2.91	-860.39	34.89	-969.59	74.01
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Vanda Pharmaceuticals (VNDA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
ROCE (%)	-49.51	53.56	-30.01	32.82	-0.17
ROE (%)	-100.43	110.09	163.18	42.98	-71.14
ROA (%)	-41.56	15.64	26.53	29.32	-16.12
EBIT Margin (%)	-83.46	21.13	5.73	31.04	-0.77
Net Margin (%)	-127.41	17.67	71.69	35.33	-47.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Vanda Pharmaceuticals (VNDA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Revenue Growth (%)	6.02	24.67	114.85	9.23	12.22
EBIT Growth (%)	-125.84	18.70	136.39	-3.99	93.17
Net Profit Growth (%)	-310.61	17.50	378.76	42.89	-115.58
EPS Growth (%)	-305.65	26.84	353.27	50.42	-73.87
Book Value Growth (%)	-55.65	164.02	816.12	-0.70	-13.57

Valuation Ratios

	Vanda Pharmaceuticals (VNDA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Price / Earnings	-2.36	36.06	-59.76	15.79	-2,869.63
Price / Book Value	1.59	35.44	-80.42	5.72	10.04
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-2.13	28.08	-121.54	12.44	25.04
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Vanda Pharmaceuticals (VNDA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debt to Equity	0.00	0.00	0.00	0.00	1.77
Short term debt to equity ratio	0.02	0.00	0.05	0.00	0.09
Current Ratio	1.61	0.73	2.99	3.46	5.90
Quick Ratio	1.60	0.73	2.32	3.38	5.90
Interest Coverage	--	--	1.62	--	-1.72

Operating Efficiency Ratios

	Vanda Pharmaceuticals (VNDA)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)
Debtors to sales (%)	27.67	15.88	21.25	13.74	1.28
Asset Turnover	0.33	0.89	0.37	0.83	0.34
Receivable days	85.93	50.42	85.52	43.48	1.50
Inventory Days	50.09	--	1,056.70	96.17	--
Payable days	118.14	6.26	331.01	147.97	221.81
Cash Conversion Cycle	17.88	--	811.21	-8.32	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly